Pathkey AI Ltd

0.028

+0.00416.67%

Volume:1.03M

Turnover:27.85K

Market Cap:8.48M

PE:-3.64

High:0.029

Open:0.025

Low:0.025

Close:0.024

52wk High:0.036

52wk Low:0.015

Shares:302.75M

Float Shares:95.62M

Volume Ratio:2.67

T/O Rate:1.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.008

EPS(LYR):-0.008

ROE:--

ROA:-185.74%

PB:-31.59

PE(LYR):-3.64

Loading ...

Overview Company News Filings

Pathkey.AI Says Analytics Platform Analyzes 42 Clinical Trials in Proof-of-Concept Study, Shares Jump 17%

MT Newswires Live

·

28 mins ago

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PKY.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PKY.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PKY.AU\",,,,,undefined,":{"symbol":"PKY.AU","market":"AU","secType":"STK","nameCN":"Pathkey AI Ltd","latestPrice":0.028,"timestamp":1758168413255,"preClose":0.024,"halted":0,"volume":1031023,"delay":0,"nameEN":"Pathkey AI Ltd","floatShares":95617819,"shares":302749044,"eps":-0.007689,"marketStatus":"Trading","change":0.004,"latestTime":"09-18 14:36:56 AEST","open":0.025,"high":0.029,"low":0.025,"amount":27850,"amplitude":0.166667,"askPrice":0.028,"askSize":243742,"bidPrice":0.025,"bidSize":318045,"shortable":3,"etf":0,"ttmEps":-0.007689,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1758175200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.024,"openAndCloseTimeList":[[1758153600000,1758175200000]],"volumeRatio":2.666534,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PKY.AU\",,,,,undefined,":{"symbol":"PKY.AU","floatShares":95617819,"roa":"-185.74%","roe":"--","lyrEps":-0.007686,"volumeRatio":2.666534,"shares":302749044,"dividePrice":0,"high":0.029,"amplitude":0.166667,"preClose":0.024,"low":0.025,"week52Low":0.015,"pbRate":"-31.59","psRate":"305.11","week52High":0.036,"institutionHeld":0,"latestPrice":0.028,"committee":0.132262,"eps":-0.007689,"divideRate":0,"volume":1031023,"delay":0,"ttmEps":-0.007689,"open":0.025,"prevYearClose":0.019,"prevWeekClose":0.028,"prevMonthClose":0.024,"prevQuarterClose":0.029,"fiveDayClose":0.027,"twentyDayClose":0.023,"sixtyDayClose":0.027},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PKY.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PKY.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PKY.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2568176440","title":"Pathkey.AI Says Analytics Platform Analyzes 42 Clinical Trials in Proof-of-Concept Study, Shares Jump 17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568176440","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568176440?lang=en_us&edition=fundamental","pubTime":"2025-09-18 12:09","pubTimestamp":1758168590,"startTime":"0","endTime":"0","summary":"Pathkey.AI  AI-powered clinical trial analytics platform, TrialKey, analyzed 42 clinical trials in peptide-based therapies for type-2 diabetes and obesity in a proof-of-concept study, identifying key molecular and patient drivers of trial success, according to a Thursday Australian bourse filing.It highlighted features such as peptide length, molecular weight, receptor binding, and patient comorbidities as critical drivers of trial success.The firm is incorporating drug-level features in TrialKey, such as molecular structure and pharmacokinetic properties, alongside traditional trial variables, allowing for AI-powered drug discovery and repurposing.Its shares jumped 17% in recent trading on Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PKY.AU","BK7016","PACI.U"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}]}}